{"product_id":"kirinholdings-business-model-canvas","title":"Kirin Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKirin Business Model Canvas: Downloadable Playbook for Investors \u0026amp; Founders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGain a clear view of Kirin's business model with our Business Model Canvas-mapping its value proposition, customer segments, key partners, and revenue streams to reveal how the company builds brand strength across beer, soft drinks, and pharmaceuticals; ideal for investors, consultants, and founders seeking practical, ready-to-use insight-download the full Word\/Excel canvas to analyze, benchmark, and plan with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alliance with Fancl Corporation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKirin holds a capital and business alliance with Fancl Corporation to bolster its Health Science unit, including a ¥5.0bn equity stake disclosed in 2023 and joint R\u0026amp;D investments of ~¥1.2bn in 2024 for co-developing functional skincare and supplements using Kirin's fermentation tech.\u003c\/p\u003e\n\u003cp\u003eBy integrating Fancl's DTC (direct-to-consumer) platform-over 2.4m loyalty members in 2024-Kirin expanded wellness channel reach, aiming for a combined Health Science revenue target of ¥40bn by FY2026.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Research Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThrough subsidiary Kyowa Kirin, Kirin holds global pharma partnerships with biotech and universities to co-develop next‑gen antibody platforms and rare‑disease therapies; as of 2025 Kyowa Kirin reported JPY 214.8 billion in pharma R\u0026amp;D commitments and over 30 active collaborations, sharing clinical risk and milestone economics to keep a steady late‑stage pipeline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution and Bottling Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKirin depends on a global network of distributors and local bottlers to keep market share abroad; in 2024 this network supported export volumes of ~1.2 million hectoliters and international sales of JPY 180 billion (about USD 1.2 bn). \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAgricultural and Raw Material Suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe company secures long-term contracts with farmers for hops, malt, and adjuncts, investing in sustainable practices and climate-resilient supply chains after a 2024 pilot cut water use by 18% and raised hop yield 12%.\u003c\/p\u003e\n\u003cp\u003eCollaborations include technical support to growers to keep Kirin Ichiban quality consistent; procurement aims to source 60% sustainable ingredients by 2030 per Kirin Group targets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLong-term contracts with growers\u003c\/li\u003e\n\u003cli\u003e2024 pilot: -18% water, +12% hop yield\u003c\/li\u003e\n\u003cli\u003eTechnical support for consistency\u003c\/li\u003e\n\u003cli\u003eTarget: 60% sustainable sourcing by 2030\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJoint Ventures in Logistics and Sustainability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eKirin joins logistics joint ventures with other beverage makers to cut delivery miles and CO2; a 2024 pilot cut route km 12% and emissions 9%, saving about ¥350 million in fuel and driver costs.\u003c\/p\u003e\n\u003cp\u003eSharing trucks raises load factors to ~85% vs 60% solo, helping meet Kirin's 2030 target of 30% Scope 3 reduction and offset rising Japanese fuel\/labor costs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12% fewer km, 9% CO2 cut (2024 pilot)\u003c\/li\u003e\n\u003cli\u003e¥350M fuel\/labor savings (2024)\u003c\/li\u003e\n\u003cli\u003eLoad factor up to ~85% vs 60%\u003c\/li\u003e\n\u003cli\u003eSupports 2030 Scope 3 -30% target\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKirin's partnerships: scaling Health Science to ¥40bn, ¥215bn pharma R\u0026amp;D \u0026amp; sustainability gains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKirin's key partnerships span a ¥5.0bn equity+¥1.2bn R\u0026amp;D alliance with Fancl (2023-24) to scale Health Science to a ¥40bn FY2026 target, Kyowa Kirin's 30+ pharma collaborations with JPY 214.8bn R\u0026amp;D commitments (2025), global distributors exporting ~1.2M hl and JPY 180bn sales (2024), farmer contracts targeting 60% sustainable sourcing by 2030, and logistics JVs cutting km 12%\/CO2 9% (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003eYear\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFancl\u003c\/td\u003e\n\u003ctd\u003e¥5.0bn equity; ¥1.2bn R\u0026amp;D; target ¥40bn HS revenue\u003c\/td\u003e\n\u003ctd\u003e2023-2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKyowa Kirin\u003c\/td\u003e\n\u003ctd\u003e30+ collaborations; JPY 214.8bn R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003e~1.2M hl; JPY 180bn sales\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrowers\u003c\/td\u003e\n\u003ctd\u003e-18% water\/+12% hop yield pilot; 60% sustainable by 2030\u003c\/td\u003e\n\u003ctd\u003e2024-2030\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLogistics JVs\u003c\/td\u003e\n\u003ctd\u003e-12% km; -9% CO2; ¥350M savings\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for Kirin that maps nine BMC blocks with clear value propositions, customer segments, channels and revenue streams aligned to real-world brewing, beverages and health science operations, ideal for investor presentations and strategic planning with linked SWOT insights and competitive advantage analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Kirin's strategy into a clean, editable one-page Business Model Canvas to save hours of structuring and enable fast boardroom-ready comparisons and collaborative adaptation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Fermentation and Biotechnology R and D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKirin invests ~¥60bn annually in R\u0026amp;D (2024), centering on advanced fermentation and biotech across beer, health sciences, and pharmaceuticals to scale proprietary ingredients like LC-Plasma; this R\u0026amp;D drove ¥12.4bn revenue from health-related products in FY2023 and supports product differentiation via clinically shown immune benefits in multiple randomized trials.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrand Management and Global Marketing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA core activity is strategic positioning and promotion of the Kirin brand across markets, with FY2024 group advertising and promotion spend about JPY 96.5 billion to support both premium beers (Kirin, Ichiban) and functional drinks (Kirin Beverage), requiring tailored campaigns per segment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Quality Control Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpkirin operates dozens of production sites across japan and asia enforcing iso food-safety in-house qc protocols to keep product consistency for kirin ichiban afternoon tea in capital expenditure on manufacturing quality control totaled billion about group capex. the company is automating lines-robotic cells ai vision-cutting takt time by pilot plants offsetting a year-on-year decline factory labor availability.\u003e\n\u003c\/pkirin\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Commercialization and Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eKirin oversees clinical trials, secures approvals, and commercializes drugs via Kyowa Kirin, which deployed specialized sales teams across Japan, Europe, and the US and reported ¥285.6bn pharma revenue in FY2024 (year to Mar 2025), up 8% YoY, driving the group's shift to life sciences and higher-margin recurring sales.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClinical\/regulatory management\u003c\/li\u003e\n\u003cli\u003eKyowa Kirin global sales force\u003c\/li\u003e\n\u003cli\u003e¥285.6bn pharma revenue FY2024\u003c\/li\u003e\n\u003cli\u003e8% YoY growth\u003c\/li\u003e\n\u003cli\u003eKey long-term profitability driver\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Environmental Sustainability Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpkirin optimizes its end-to-end supply chain to cut waste and shrink packaging emissions rolling out recycled pet bottles across japan using brewery water-saving tech that reduced water use per hectoliter by versus levels. managing these programs is now core corporate strategy with kirin targeting net-zero scope allocating billion sustainability investments.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003e100% recycled PET deployment in 2024 rollouts\u003c\/li\u003e\n\u003cli\u003eWater use down 18% per hL since 2018\u003c\/li\u003e\n\u003cli\u003eNet-zero scope 1\/2 target: 2035\u003c\/li\u003e\n\u003cli\u003e¥30 billion sustainability capex (2024-2026)\u003c\/li\u003e\n\n\u003c\/pkirin\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKirin: ¥60bn R\u0026amp;D, ¥96.5bn marketing, ¥285.6bn pharma, automated CAPEX \u0026amp; green push\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKirin runs R\u0026amp;D (~¥60bn\/2024), global brand marketing (¥96.5bn\/2024), dozens of automated production sites (CAPEX ¥45.2bn\/2024), Kyowa Kirin pharma commercialization (¥285.6bn revenue FY2024, +8% YoY), and sustainability programs (100% recycled PET 2024, -18% water per hL vs 2018, ¥30bn sostenability capex 2024-26).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003eKey 2024-25 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e¥60bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarketing\u003c\/td\u003e\n\u003ctd\u003e¥96.5bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing CAPEX\u003c\/td\u003e\n\u003ctd\u003e¥45.2bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma revenue\u003c\/td\u003e\n\u003ctd\u003e¥285.6bn FY2024 (+8%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSustainability\u003c\/td\u003e\n\u003ctd\u003e100% PET, -18% water, ¥30bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Kirin Business Model Canvas preview shown here is the actual deliverable-not a mockup or sample-and reflects the same structure and content you will receive after purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you'll get the full, editable file in the same format, ready for presentation, editing, and implementation with no hidden sections or surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Fermentation and Cell Culture Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKirin leverages 100+ years of brewing biology and a proprietary strain library to build fermentation and cell‑culture platforms; this tech underpinned JPY 72.3bn (2024) health‑science sales and enabled a 2023 R\u0026amp;D pipeline with 12 immunology candidates, giving Kirin a rare food‑to‑medicine moat that cut new ingredient development time by ~40% versus industry averages.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Global Brand Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKirin's global brand portfolio-led by Kirin Ichiban, San Miguel (Kirin-controlled stake via San Miguel Brewery Philippines), and Kyowa Kirin's pharmaceutical brands-supports premium pricing and cross-category trust, contributing to consolidated brand-driven margins (Kirin Holdings reported operating profit margin ~7.8% in FY2024). These intangible assets are defended by extensive trademarks (thousands registered globally) and sustained marketing spend-Kirin invested ~¥75 billion in SG\u0026amp;A\/marketing in FY2024-to maintain equity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eModern Production and R and D Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKirin operates over 60 breweries, 40 bottling plants, and 12 pharmaceutical labs worldwide (2024), with \u0026gt;70% of sites using advanced automation and 45% powered by renewables, cutting per-unit energy costs ~18% and CO2 emissions 22% vs 2018; regional footprints in Japan, ASEAN, Australia, and Brazil reduce average transport distance 30%, lowering logistics spend and improving local market responsiveness.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHuman Capital and Scientific Expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eKirin employs ~8,500 staff globally (2024), including scientists, brewmasters, and strategists; their R\u0026amp;D spend was ¥78.3 billion in FY2024, driving new products in beverages and pharma.\u003c\/p\u003e\n\u003cp\u003eResearchers' expertise in antibody tech and microbiology underpins Kirin's Kyowa Kirin pharma arm; ongoing training and \u0026gt;1,200 active R\u0026amp;D projects keep innovation pipeline robust.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e8,500 employees (2024)\u003c\/li\u003e\n\u003cli\u003e¥78.3 billion R\u0026amp;D (FY2024)\u003c\/li\u003e\n\u003cli\u003eKyowa Kirin integration: antibody expertise\u003c\/li\u003e\n\u003cli\u003e~1,200 active R\u0026amp;D projects\u003c\/li\u003e\n\u003cli\u003eContinuous training culture\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Distribution and Retail Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eKirin's long-standing contracts with wholesalers, retailers, and over 2,000 medical institutions in Japan secure shelf space across convenience stores, ~3.5 million vending machines nationwide, and hospital supply chains, making product availability consistently high and raising entry costs for smaller rivals.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2,000+ medical partners\u003c\/li\u003e\n\u003cli\u003e~3.5M vending machines distribution\u003c\/li\u003e\n\u003cli\u003eWide convenience-store shelf presence\u003c\/li\u003e\n\u003cli\u003eHigh fixed-cost barrier for entrants\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKirin: Brewing a century of biology-¥78bn R\u0026amp;D, ¥72bn health sales, 3.5M vending machines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKirin's key resources: 8,500 employees, ¥78.3bn R\u0026amp;D (FY2024), 100+ years brewing biology, 60+ breweries, 12 pharma labs, 1,200 R\u0026amp;D projects, ¥72.3bn health‑science sales (2024), ~3.5M vending machines, 2,000+ medical partners, ¥75bn marketing (FY2024), 45% sites on renewables.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmployees\u003c\/td\u003e\n\u003ctd\u003e8,500\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e¥78.3bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealth‑science sales\u003c\/td\u003e\n\u003ctd\u003e¥72.3bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBreweries\u003c\/td\u003e\n\u003ctd\u003e60+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVending machines\u003c\/td\u003e\n\u003ctd\u003e~3.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePremium Quality and Authentic Brewing Heritage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKirin positions premium quality via Kirin Ichiban's first-press (shibori) method, marketed as delivering cleaner flavor and 20-35% higher malt purity versus standard brewing; this appeals to discerning drinkers valuing tradition and refined taste, helping Kirin Holdings Co., Ltd. report ¥2.3 trillion revenue in FY2024 and sustain 6-8% premium-segment growth in key markets, reinforcing Japanese craftsmanship and global reliability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScience-Based Health and Wellness Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKirin sells science-backed functional foods and drinks-like LC-Plasma immune-support products-bringing peer-reviewed research into everyday grocery items; in 2024 Kirin's health-beverage segment grew ~8% y\/y and LC-Plasma SKUs reached national rollout in Japan, contributing roughly JPY 18 billion in annual sales, meeting rising demand for proactive daily health management where 62% of Japanese consumers cite prevention as purchase driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLife-Changing Pharmaceutical Treatments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThrough Kirin's pharmaceutical arm, the company delivers specialty oncology and nephrology drugs that target unmet needs-treating rare and chronic conditions with therapies that raised 2024 pharma revenues to ¥185.3 billion and achieved 28% year-on-year growth in specialty sales; clinical programs include multiple Phase III assets aimed at improving survival and dialysis-independence rates, concentrating R\u0026amp;D spend to maximize high-impact medical advances.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSustainable and Socially Responsible Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eKirin sells eco-friendly-packaged drinks with traceable sourcing, targeting younger, purpose-driven consumers; its 2024 sustainability report shows 42% recycled packaging use and a 12% year-over-year rise in sales to consumers under 35.\u003c\/p\u003e\n\u003cp\u003eThat focus helps grow revenue without worsening emissions: Kirin reported a 9% cut in Scope 1-2 emissions (2020-2024) while maintaining 3.2% CAGR in organic volume sales.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e42% recycled packaging (2024)\u003c\/li\u003e\n\u003cli\u003e12% sales rise under-35 (YoY 2024)\u003c\/li\u003e\n\u003cli\u003e9% Scope 1-2 emissions cut (2020-2024)\u003c\/li\u003e\n\u003cli\u003e3.2% organic volume CAGR\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiverse Portfolio for Every Lifestyle\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eKirin offers a full range of drinks-nonalcoholic beverages, craft beers, and spirits-covering occasions from moderation to indulgence and matching shifts in consumer taste; in 2024 Kirin Holdings reported ¥1.7 trillion consolidated revenue, with nonalcoholic and craft segments growing faster than overall volume. The brand's multi‑channel distribution-convenience stores, supermarkets, e‑commerce, and on‑trade-boosts availability and repeat purchases.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRange: nonalcoholic, craft beer, spirits\u003c\/li\u003e\n\u003cli\u003e2024 revenue: ¥1.7 trillion (Kirin Holdings)\u003c\/li\u003e\n\u003cli\u003eChannels: convenience, supermarket, e‑commerce, on‑trade\u003c\/li\u003e\n\u003cli\u003eBenefit: meets moderation and indulgence shifts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKirin: Premium brews, science-backed health drinks and sustainability fuel ¥2.3T growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKirin's value props: premium-brew quality (Ichiban shibori) driving premium-segment growth; science-backed health drinks (LC-Plasma) and specialty pharma delivering high-margin sales; sustainability and diverse beverage range boosting young-consumer and omni‑channel uptake, supporting FY2024 group revenue ~¥2.3T and pharma ¥185.3B.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGroup revenue\u003c\/td\u003e\n\u003ctd\u003e¥2.3T\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma revenue\u003c\/td\u003e\n\u003ctd\u003e¥185.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecycled packaging\u003c\/td\u003e\n\u003ctd\u003e42%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrand Loyalty and Community Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKirin deepens customer ties via digital platforms and a loyalty program that drove a 12% repeat-purchase uplift in FY2024, rewarding points redeemable for products and event access. By running social campaigns and 1,200 local events in 2024, Kirin built active communities that helped sustain stable domestic market share of 18.5% in beer and beverages.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eB2B Professional Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKirin keeps tight B2B ties with restaurant owners, bar managers, and retailers via dedicated sales reps and equipment maintenance contracts, supporting over 45,000 on‑trade outlets in Japan as of FY2024 and driving ~28% of on‑premise volume. The company adds staff training, POS and promotional materials, and co‑op marketing (Kirin reported ¥18.6bn in trade promotion spend in 2024) so partners boost sales and prefer Kirin as supplier.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient and Healthcare Provider Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKirin builds trust with healthcare providers by delivering peer-reviewed clinical data and CME (continuing medical education) resources; in 2024 Kirin funded \u0026gt;1200 HCP trainings and published 18 phase‑III analyses to support prescribing confidence. The company runs patient support programs-nurse hotlines, co-pay assistance, and adherence apps-that served ~45,000 specialty patients in 2024 to improve safety and outcomes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Consumer Digital Interaction\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eKirin's partnership with Fancl and its own e-commerce channels serve 1.2M annual DTC visitors (2024), collecting purchase and preference data that raise repeat-buy rates by about 18% through personalized recommendations.\u003c\/p\u003e\n\u003cp\u003eDirect messaging and reviews deliver real-time feedback used to adjust formulations, contributing to a 6% revenue uplift in the health-science portfolio in FY2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e1.2M DTC visitors (2024)\u003c\/li\u003e\n\u003cli\u003e+18% repeat-buy from personalization\u003c\/li\u003e\n\u003cli\u003e6% portfolio revenue uplift FY2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCorporate Social Responsibility Communication\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eKirin reports sustainability progress and social programs to stakeholders to build long-term trust, citing a 2024 group-wide 28% reduction in scope 1+2 emissions vs 2015 and JPY 4.2bn in community investments in FY2023 to show impact.\u003c\/p\u003e\n\u003cp\u003eTransparent targets and annual ESG disclosures help sustain investor and public support, reflected in Kirin Holdings' 2024 ESG-linked loan facility of JPY 50bn tied to emissions and water targets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e28% cut in scope 1+2 emissions vs 2015\u003c\/li\u003e\n\u003cli\u003eJPY 4.2bn community investment in FY2023\u003c\/li\u003e\n\u003cli\u003eJPY 50bn ESG-linked loan (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKirin drives loyalty and growth: 12% repeat uplift, 1.2M DTC, ¥18.6bn trade spend\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKirin deepens consumer loyalty via digital channels and a points program (12% repeat uplift FY2024), 1.2M DTC visitors and +18% personalization repeat-buy; B2B sales reps and ¥18.6bn trade spend support 45,000 outlets and ~28% on‑premise volume; health‑science patient programs served ~45,000 patients and drove a 6% portfolio uplift FY2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 \/ FY\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDTC visitors\u003c\/td\u003e\n\u003ctd\u003e1.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRepeat uplift (loyalty)\u003c\/td\u003e\n\u003ctd\u003e12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePersonalization repeat-buy\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrade promotion spend\u003c\/td\u003e\n\u003ctd\u003e¥18.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn‑trade outlets\u003c\/td\u003e\n\u003ctd\u003e45,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn‑premise volume\u003c\/td\u003e\n\u003ctd\u003e~28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients served (health)\u003c\/td\u003e\n\u003ctd\u003e~45,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealth portfolio revenue uplift\u003c\/td\u003e\n\u003ctd\u003e6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMass Retail and Convenience Store Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA majority of Kirin Holdings Co., Ltd.'s beverage sales-about 62% of retail volume in FY2024-flow through supermarkets, convenience stores, and drugstores, making products like Kirin Gogo-no-Kocha broadly available to commuters and shoppers; Kirin reports over 210,000 retail outlets in Japan alone. The company uses shelf-space management and category optimization, driving a 4-6% uplift in unit sales per promoted SKU in convenience channels.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOn-Premise Bars and Restaurants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKirin's beers and spirits are core offerings in izakayas, bars and fine-dining venues in Japan and Australia, driving on-premise volume that represented about 28% of Kirin Holdings' beverage sales in FY2024 (ended Dec 2024). Dedicated sales teams secure tap placements and exclusive pouring rights in key venues, boosting brand visibility and average on-premise spend per consumer by an estimated 12% vs retail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Sales Representatives and Medical Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe pharmaceutical division uses a specialized field force of medically trained reps to call on doctors and hospital admins, delivering technical data and patient-appropriate evidence for specialty drug prescriptions; in 2024 Kirin reported pharmaceutical sales of JPY 112.3 billion, with detailing-driven products accounting for ~68% of that revenue. This channel is tightly regulated (Japan PMDA rules), prioritizes professional expertise over mass marketing and drives higher margin, lower-volume sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVending Machine Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eKirin runs ~2.1 million vending machines across Japan, giving 24-7 access to soft drinks and functional beverages and acting as constant brand touchpoints in cities and rural areas.\u003c\/p\u003e\n\u003cp\u003eMachines serve as live testbeds for new SKUs and collect localized sales data-Kirin reported vending-channel sales of ¥120 billion in FY2024, with pilot launches raising regional SKU sell-through by ~18%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~2.1 million machines nationwide\u003c\/li\u003e\n\u003cli\u003e24-7 retail \u0026amp; brand presence\u003c\/li\u003e\n\u003cli\u003e¥120 billion vending sales FY2024\u003c\/li\u003e\n\u003cli\u003eNew-SKU pilot uplift ~18%\u003c\/li\u003e\n\u003cli\u003eGranular, localized sales telemetry\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eE-commerce and Subscription Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eKirin is growing online via direct-to-consumer sales and third-party marketplaces such as Amazon, driving a 22% e-commerce revenue uplift in FY2024 and cutting distribution costs by ~8%.\u003c\/p\u003e\n\u003cp\u003eSubscription offerings-monthly health supplement plans and a home-delivery beer-on-tap service-represent 12% of digital sales, improve ARPU, and raise 12-month retention to 68%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2024 e-commerce +22%\u003c\/li\u003e\n\u003cli\u003eDistribution cost -8%\u003c\/li\u003e\n\u003cli\u003eSubscriptions =12% digital sales\u003c\/li\u003e\n\u003cli\u003e12-month retention 68%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKirin: omnichannel scale-mass retail \u0026amp; 2.1M vending + fast‑growing e‑commerce fueling margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKirin's channels mix-62% retail, 28% on‑premise, ¥120B vending, and growing e‑commerce (+22% FY2024)-balances mass reach (210,000+ retail outlets, ~2.1M vending machines) with high‑margin specialty pharma (¥112.3B sales) and subscriptions (12% digital sales, 68% 12‑month retention), driving SKU uplifts (4-6% promo, 18% vending pilots) and ~8% distribution cost savings online.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail share\u003c\/td\u003e\n\u003ctd\u003e62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn‑premise\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail outlets (JP)\u003c\/td\u003e\n\u003ctd\u003e210,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVending machines\u003c\/td\u003e\n\u003ctd\u003e~2.1M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVending sales FY2024\u003c\/td\u003e\n\u003ctd\u003e¥120B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma sales FY2024\u003c\/td\u003e\n\u003ctd\u003e¥112.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eE‑commerce growth FY2024\u003c\/td\u003e\n\u003ctd\u003e+22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSubscription share (digital)\u003c\/td\u003e\n\u003ctd\u003e12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e12‑month retention\u003c\/td\u003e\n\u003ctd\u003e68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePromo uplift (conv.)\u003c\/td\u003e\n\u003ctd\u003e4-6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVending pilot uplift\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistribution cost online\u003c\/td\u003e\n\u003ctd\u003e-8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMass Market Beverage Consumers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThis segment covers broad demographics buying beer, soft drinks, and tea for everyday use; they value taste, price, and wide availability. In 2024 Kirin Group reported JPY 1.09 trillion in revenue and used its nationwide retail network and mass-media campaigns to serve ~40% of Japan's beverage market by volume, focusing promotions and price tiers to keep shelf share and repeat purchase rates high.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth-Conscious and Aging Populations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKirin targets proactive health-conscious and aging consumers-Japan's 65+ population hit 29.1% in 2024-seeking functional foods and drinks for immune support and digestion; its Health Science unit posted ¥125.4 billion revenue in FY2023, focusing R\u0026amp;D and products like lactoferrin and pre\/probiotics to capture rising demand and a market estimated at ¥1.8 trillion for functional foods in Japan (2024).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatients with Specialty Medical Needs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKirin targets patients with specialty needs-nephrology and rare-disease cohorts-where global orphan drug sales hit $178B in 2024 and nephrology biologics grew 9% YoY; these patients need long-term, high-cost care (average annual therapy \u0026gt;$100k). Kirin's R and D focuses on disease-modifying, life-saving therapies with pipeline assets and targeted trials to capture this niche, high-value segment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePremium and Craft Beer Enthusiasts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThis segment pays more for novel flavors and artisanal methods; Kirin targets them via craft subsidiaries like Spring Valley and limited-edition cans, with craft beer sales up ~12% in Japan in 2024 and premium SKUs contributing ~18% of Kirin Holdings' domestic beer revenue in FY2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eYounger, experimental drinkers (ages ~25-40)\u003c\/li\u003e\n\u003cli\u003eWilling to pay 10-30% premium per SKU\u003c\/li\u003e\n\u003cli\u003eReach via limited runs, taprooms, collabs\u003c\/li\u003e\n\u003cli\u003eCraft contributed ~¥60-80bn to FY2024 beer sales\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Business and Institutional Clients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpkirin serves restaurants hotels and healthcare facilities worldwide supplying beverages ingredients through stable logistics account management institutional sales made up about of kirin group revenues in fy2024 march underscoring how managing these contracts preserves market share.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003eCore B2B: restaurants, hotels, healthcare\u003c\/li\u003e\n\u003cli\u003eFY2024 institutional share: ~28%\u003c\/li\u003e\n\u003cli\u003eNeeds: reliable supply chain, professional support\u003c\/li\u003e\n\u003cli\u003eKey metric: contract retention drives market share\u003c\/li\u003e\n\n\u003c\/pkirin\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKirin's diversified customer mix: mass, health \u0026amp; seniors, specialty patients, craft, B2B\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpkirin customer segments span mass-market beverage buyers japan volume jpy1.09t revenue health-conscious consumers in health science fy2023 specialty patients market nephrology biologics yoy craft-premium domestic beer fy2024 craft and b2b institutional accounts group\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024\/ FY2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMass market\u003c\/td\u003e\n\u003ctd\u003eShare \/ Revenue\u003c\/td\u003e\n\u003ctd\u003e≈40% vol \/ JPY1.09T\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealth-conscious \u0026amp; 65+\u003c\/td\u003e\n\u003ctd\u003ePopulation \/ Revenue\u003c\/td\u003e\n\u003ctd\u003e65+ =29.1% \/ ¥125.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty patients\u003c\/td\u003e\n\u003ctd\u003eMarket \/ Growth\u003c\/td\u003e\n\u003ctd\u003eOrphan $178B \/ nephrology +9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCraft \u0026amp; premium\u003c\/td\u003e\n\u003ctd\u003eContribution \/ Growth\u003c\/td\u003e\n\u003ctd\u003e18% rev \/ +12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eB2B institutional\u003c\/td\u003e\n\u003ctd\u003eRevenue share\u003c\/td\u003e\n\u003ctd\u003e≈28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/pkirin\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRaw Material and Commodity Procurement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe largest cost for Kirin Holdings in beverages is raw materials-malt, hops and sugar-accounting for roughly 18-22% of COGS; global commodity swings and a ±10% forex move can cut margins by ~1-2ppt. Kirin uses FX hedges and multi-year supply contracts (covering ≈40-60% of volumes) and reported commodity-related hedging gains\/losses of ¥12.4bn in FY2024 to stabilize input costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKirin Holdings invests heavily in R\u0026amp;D, spending ¥69.4 billion in FY2024 (consolidated) with most directed to its pharmaceuticals and health-science units; drug and functional-ingredient development often takes 8-12 years and costs hundreds of millions per compound with no guaranteed approval.\u003c\/p\u003e\n\u003cp\u003eThese high, long-tail expenditures are essential to sustain biotech competitiveness and revenue growth-Kirin cites pipeline-driven targets to raise pharma sales by ~25% by FY2027, so R\u0026amp;D remains a strategic priority despite short-term margin pressure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarketing and Advertising Expenditures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKirin allocates roughly 8-10% of net sales to marketing, about ¥85 billion in FY2024 (ended Dec 2024), funding digital ads, sports sponsorships (J.League, regional teams) and point-of-sale displays to defend share against AB InBev and Heineken. These promotional costs are critical for new-product launches-Kirin spent ¥12 billion on the 2024 launch campaign for a ready-to-drink RTD line-and to sustain established brands' distribution and awareness.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Logistics Overhead\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOperating Kirin's large-scale breweries and a global fleet drives high energy, labor, and maintenance costs-Japan beverage peers report manufacturing SG\u0026amp;A at ~18-22% of revenue in 2024; Kirin's efficiency push targets a 5-7% cut via automation and SC optimization.\u003c\/p\u003e\n\u003cp\u003eRising fuel ( Brent-linked freight up ~28% in 2024 vs 2023) and logistics labor shortages keep costs volatile, so Kirin emphasizes route optimization and robotics in warehousing to hedge margin pressure.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eManufacturing SG\u0026amp;A ~18-22% revenue\u003c\/li\u003e\n\u003cli\u003eTargeted cost cut 5-7% via automation\u003c\/li\u003e\n\u003cli\u003eFreight costs +28% in 2024 vs 2023\u003c\/li\u003e\n\u003cli\u003eLogistics labor shortages raise overtime, temp hires\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Quality Assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory compliance and quality assurance demand ongoing spend-clinical trials (phase I-III average $10m-$50m per program globally in 2024), GMP factory audits (~$50k-$200k per inspection), and patent\/legal fees (~$200k+ annually for major IP portfolios).\u003c\/p\u003e\n\u003cp\u003eThese costs are non-negotiable for a health-and-wellness firm like Kirin to access markets and maintain trust.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClinical trials: $10m-$50m per program (2024)\u003c\/li\u003e\n\u003cli\u003eFactory inspections: $50k-$200k each\u003c\/li\u003e\n\u003cli\u003eIP\/legal: $200k+ annually\u003c\/li\u003e\n\u003cli\u003eOngoing QA systems: 1-3% of revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKirin margins squeezed: raw materials, SG\u0026amp;A, marketing and freight drive FY2024 volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKirin's largest costs are raw materials (malt, hops, sugar ~18-22% COGS) and manufacturing SG\u0026amp;A (~18-22% revenue); FY2024 hedging gains ¥12.4bn and R\u0026amp;D ¥69.4bn drive volatility. Marketing ≈¥85bn (8-10% sales) and logistics (freight +28% y\/y 2024) add pressure; compliance (trials $10-50m\/program) is non-negotiable.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eFY2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e¥69.4bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHedging gains\u003c\/td\u003e\n\u003ctd\u003e¥12.4bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarketing\u003c\/td\u003e\n\u003ctd\u003e¥85bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFreight change\u003c\/td\u003e\n\u003ctd\u003e+28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales of Alcoholic Beverages\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary revenue stream is sale of beer, sparkling spirits, and wine in Japan and abroad, led by Kirin Ichiban which accounted for about ¥500 billion (~$3.5B) of group beverage sales in FY2024; local brands in Southeast Asia and Australia add high-volume tails. Sales mix combines wholesale to retailers (supermarkets, convenience stores) and direct on-premise supply to bars and restaurants, with exports and overseas subsidiaries contributing roughly 30% of alcoholic beverage revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Product Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKirin earns major revenue from specialty drugs via Kyowa Kirin, with pharmaceuticals accounting for about 60% of consolidated sales; in FY2024 (ended Mar 31, 2024) Kyowa Kirin reported JPY 268.4 billion in pharmaceutical revenue, led by high-margin rare-disease blockbusters that materially boost group profitability and cash flow stability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-Alcoholic and Functional Beverage Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRevenue comes from sales of soft drinks, teas and functional beverages such as the iMUSE probiotic line; Kirin's non‑alcoholic unit generated ¥320 billion in FY2024 (ended Dec 2024), up 4.5% YoY, driven by health‑oriented SKUs. Demand for wellness drinks rose 6% in Japan 2024, and Kirin distributes via mass retail, foodservice and its ~1.7 million vending machines nationwide, which account for roughly 25% of channel volume.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth Science and Functional Ingredient Licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eKirin earns B2B revenue by selling proprietary health ingredients-like lactic acid bacteria strains and amino-acid derivatives-to food and supplement makers, and reported JPY 42.5 billion in wellness ingredient sales in FY2024.\u003c\/p\u003e\n\u003cp\u003eThe company also takes royalties from licensing fermentation tech and pharmaceutical patents, contributing to 8-12% of group recurring revenue and leveraging IP for scalable margins.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eJPY 42.5B wellness ingredient sales FY2024\u003c\/li\u003e\n\u003cli\u003e8-12% recurring revenue from licenses\u003c\/li\u003e\n\u003cli\u003eRevenue mix: product sales + royalties\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Consumer and Subscription Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eKirin has grown online direct-to-consumer supplement and home-brewing system sales to 22% of total revenue in 2025, with subscription plans contributing 14% and delivering predictable monthly ARPU of $27.\u003c\/p\u003e\n\u003cp\u003eSubscriptions boosted 12-month customer lifetime value (LTV) by 38% and reduced churn to 4.8% after launching tiered plans in Q3 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e22% revenue from DTC (2025)\u003c\/li\u003e\n\u003cli\u003e14% from subscriptions (2025)\u003c\/li\u003e\n\u003cli\u003eARPU $27\/month\u003c\/li\u003e\n\u003cli\u003eLTV +38% (12 months)\u003c\/li\u003e\n\u003cli\u003eChurn 4.8% post-Q3 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKirin FY24: Beverages dominate ¥500B Ichiban; DTC growth fuels recurring revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKirin's revenue mix: beverages (beer, spirits, wine) ~70% of FY2024 group beverage sales with Kirin Ichiban ≈ ¥500B; pharmaceuticals (Kyowa Kirin) ≈ ¥268.4B; non‑alcoholic drinks ¥320B; wellness ingredients ¥42.5B; licenses 8-12% recurring; DTC 22% (2025) with subscriptions 14%, ARPU $27, LTV +38%, churn 4.8%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003eFY\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBeer \u0026amp; spirits\u003c\/td\u003e\n\u003ctd\u003e¥500B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma\u003c\/td\u003e\n\u003ctd\u003e¥268.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon‑alc\u003c\/td\u003e\n\u003ctd\u003e¥320B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWellness ing.\u003c\/td\u003e\n\u003ctd\u003e¥42.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDTC \/ Sub\u003c\/td\u003e\n\u003ctd\u003e22% \/ 14%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57354819174731,"sku":"kirinholdings-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/kirinholdings-canvas-business-model.webp?v=1779146701","url":"https:\/\/valuechainanalysis.com\/products\/kirinholdings-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}